Inetetamab
- Generic Name
- Inetetamab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
Inetetamab is a trastuzumab analog. It differs from trastuzumab by a two amino acid variation in its Fc domain (allotype variation), and possesses an exact F(ab’)2 of trastuzumab.
- Indication
本品用于HER2阳性的转移性乳腺癌。与长春瑞宾联合治疗接受过1个或多个化疗方案的转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
The Efficacy and Safety of Different Combination Regimens of Inetetamab in First-line Treatment of HER2 Positive Metastatic Breast Cancer
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Target Recruit Count
- 200
- Registration Number
- NCT06641544
- Locations
- 🇨🇳
Sun Yat sen Memorial Hospital of Sun Yat sen University Shenzhen Shantou Central Hospital, Shanwei, Guangdong, China
Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Liaoning Tumor Hospital & Institute
- Target Recruit Count
- 500
- Registration Number
- NCT06305702
- Locations
- 🇨🇳
Liaoning Cancer Hospital &Institue, Shenyang, China
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-31
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Wang Ouchen
- Target Recruit Count
- 154
- Registration Number
- NCT06234137
- Locations
- 🇨🇳
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
A Real-world Study of Inetetamab for First-line Treatment of MBC
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05980208
Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-09-14
- Target Recruit Count
- 30
- Registration Number
- NCT05823623
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Inetetamab Combined With Pyrotinib and Vinorelbine as First-line to Third-line Treatment for HER2-positive Metastatic Breast Cancer
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-03-27
- Target Recruit Count
- 100
- Registration Number
- NCT05764941
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)
- Conditions
- Interventions
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05328440
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Inetetamab Combined With Anti-PD-1 Monoclonal Antibody and Albumin-Bound Paclitaxel for HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 70
- Registration Number
- NCT05291910
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy Of Medical Sciences, Beijing, China
Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 48
- Registration Number
- NCT05016544
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
RWS of Inetetamab HER2 Positive Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Zhiyong Yu
- Target Recruit Count
- 100
- Registration Number
- NCT04963608
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.